IFN-alpha 2b

IFN-alpha 2b Overview

English NameInterferon alpha-2Approved Drugs1
Drugs in Clinical Trials7Target SynonymIFNA2B,IFNA2C,LeIF A,Interferon alpha-2,IFN-alpha-2,IFNA2,Interferon Alpha 2,Alpha-2a Interferon,Interferon Alpha 2b,Interferon Alpha A,Interferon Alpha 2a,Interferon Alpha-A,IFN-AlphaA,IFNA2A,INFA2,IFNA
Highest Development StageApproved
English NameInterferon alpha-2
Target SynonymIFNA2B,IFNA2C,LeIF A,Interferon alpha-2,IFN-alpha-2,IFNA2,Interferon Alpha 2,Alpha-2a Interferon,Interferon Alpha 2b,Interferon Alpha A,Interferon Alpha 2a,Interferon Alpha-A,IFN-AlphaA,IFNA2A,INFA2,IFNA
Approved Drugs1
Drugs in Clinical Trials7
Highest Development StageApproved

IFN-alpha 2b Product List

  • Product Category

    Protein (2)

  • Product Status

    Launched (2)

  • Species

    Human (2)

  • Tag

    Fc Tag (1)His Tag & Avi Tag (1)

  • Conjugate

    Unconjugated (1)Biotin-labeled (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
IFB-H5253
Human
HEK293
Human IFN-alpha 2b Protein, Fc Tag (MALS verified)
IFB-H82E3
Human
HEK293
Biotinylated Human IFN-alpha 2b Protein, His,Avitag™ (MALS verified)
Total: 2
  • 1

IFN-alpha 2b Background

IFN-alpha is a cytokine that has an immunomodulatory function. It plays an important role not only in antiviral activity but also in several physiologic functions, such as activation of dendritic cells and accelerated expression of major histocompatibility complex I and II molecules that may cause increased antigen presentation. Variants of human leukocyte interferon alpha 2 (IFN-alpha 2a, alpha 2b, and alpha 2c) differ from each other by changes in their coding regions at nucleotide positions 137 and 170. IFN-alpha 2b (IFNα-2b) is an important cytokine and used for antiviral and anticancer treatment.

IFN-alpha 2b Synonyms

IFN-alpha 2b,IFNA2B,IFN-alpha 2 (alpha 2b),interferon alpha 2b

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science)Phase 2 ClinicalGenenta Science SrlCarcinoma, Renal Cell; Glioblastoma; Multiple Myeloma
Details
Q101-pegylated interferon alfa-2a (CSPC Zhongqi Pharmaceutical Technology)Phase 1 ClinicalCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co LtdHepatitis B, Chronic
Details
PEGylated interferon alpha-1b (Shanghai Institute of Biological Products)Phase 1 ClinicalShanghai Institute of Biological Products Co LtdNeoplasms; Varicella Zoster Virus Infection; Hepatitis B
Details
SFR-1882SFR-1882Phase 1 ClinicalTianjin Sinobiotech LtdAnemia; Renal Insufficiency
Details
CX-801CX-801Phase 1 ClinicalCytomx Therapeutics IncSolid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma
Details
interferon alfa-2b follow-on biologic (Amoytop)ClinicalXiamen Amoytop Biotech Co LtdLeukemia, Hairy Cell; Lymphoma, Follicular; Hepatitis B; Hepatitis C; Melanoma; Condylomata Acuminata; Sarcoma, Kaposi
Details
interferon-alpha2b (The University Health Network)ClinicalUniversity Health Network (Uhn)Coronavirus Disease 2019 (COVID-19)
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Nadofaragene firadenovecSCH-721015ApprovedSchering - Plough Sa, Fkd TherapiesAdstiladrinUnited StatesUrinary Bladder NeoplasmsFerring Pharmaceuticals A/S2022-12-16Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Mesothelioma
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information